ストックスクリーナーアプリを入手
420.89
0.87%
3.68
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Whalen Wealth Management Inc. Purchases New Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Jennison Associates LLC Has $2.74 Billion Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Appoints New Leader in Europe to Advance Product Innovation and Strengthen Compliance - GlobeNewswire Inc.
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potential2025 Top Gainers & Fast Gain Stock Tips - newser.com
Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain markets2025 Earnings Impact & Reliable Price Action Trade Plans - newser.com
Will Vertex Pharmaceuticals Incorporated benefit from macro trends2025 Valuation Update & Fast Exit and Entry Trade Guides - newser.com
How big funds are accumulating Vertex Pharmaceuticals Incorporated (VX1) stockJuly 2025 Reactions & Daily Profit Focused Screening - newser.com
Is Vertex Pharmaceuticals Incorporated stock supported by innovation pipeline2025 Geopolitical Influence & High Accuracy Investment Signals - newser.com
Visual analytics tools that track Vertex Pharmaceuticals Incorporated performanceQuarterly Market Review & Step-by-Step Trade Execution Guides - newser.com
How Vertex Pharmaceuticals Incorporated (VX1) stock compares with top peersPortfolio Value Report & Daily Technical Stock Forecast Reports - newser.com
Vertex Pharmaceuticals (VRTX) Stock Moves -1.23%: What You Should Know - Yahoo! Finance UK
Published on: 2025-10-29 04:32:30 - newser.com
Is Vertex Pharmaceuticals Incorporated (VX1) stock a buy on weaknessJuly 2025 Big Picture & High Accuracy Trade Signal Alerts - newser.com
Transcend Capital Advisors LLC Sells 1,522 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Can machine learning forecast Vertex Pharmaceuticals Incorporated recoveryEntry Point & High Conviction Buy Zone Picks - newser.com
H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX) - Insider Monkey
Vertex Pharmaceuticals Stock Rises 8.9% as Pipeline Progress Renews Valuation Debate - Yahoo Finance
Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings (VRTX) - Seeking Alpha
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Yahoo Finance
Real time pattern detection on Vertex Pharmaceuticals Incorporated stockTrade Risk Assessment & Daily Entry Point Trade Alerts - newser.com
Howard Capital Management Inc. Acquires 2,282 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Motley Fool Asset Management LLC Purchases 1,875 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Motley Fool Wealth Management LLC Purchases 20,864 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Published on: 2025-10-28 05:03:31 - newser.com
Fjarde AP Fonden Fourth Swedish National Pension Fund Buys 17,200 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Momentum divergence signals in Vertex Pharmaceuticals Incorporated chartPortfolio Update Summary & Pattern Based Trade Signal System - newser.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by AustralianSuper Pty Ltd - MarketBeat
Will Vertex Pharmaceuticals Incorporated bounce back from current supportDay Trade & Free Risk Controlled Daily Trade Plans - newser.com
Envestnet Asset Management Inc. Has $199.89 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Using data tools to time your Vertex Pharmaceuticals Incorporated exitForecast Cut & Weekly Consistent Profit Watchlists - newser.com
Long term hold vs stop loss in Vertex Pharmaceuticals IncorporatedWeekly Profit Recap & Weekly Watchlist of Top Performers - newser.com
Vertex Pharmaceuticals Advances VX-407 Study for ADPKD - TipRanks
Vertex Pharmaceuticals Advances Pain Management with Suzetrigine Study - TipRanks
Vertex Pharmaceuticals’ VX-993 Study: A Potential Game-Changer for Diabetic Neuropathy - TipRanks
Vertex Pharmaceuticals’ Inaxaplin Study: A Potential Game-Changer in Kidney Disease Treatment - TipRanks
Vertex Pharmaceuticals Advances in DPN Treatment with Suzetrigine Study - TipRanks
Vertex Pharmaceuticals’ VX-828 Study: A New Hope for Cystic Fibrosis Treatment - TipRanks
Vertex Pharmaceuticals Advances Genetic Research in ADPKD with New Study - TipRanks
Vertex Pharmaceuticals Advances Phase 3 Study on Suzetrigine for Diabetic Neuropathy Pain - TipRanks
Vertex Pharmaceuticals’ Suzetrigine Study: A New Frontier in Pain Management - TipRanks
Vertex and Moderna’s VX-522 Study: A Potential Breakthrough in Cystic Fibrosis Treatment - TipRanks
Vertex Pharmaceuticals Advances in Kidney Disease Treatment with VX-147 Study - TipRanks
Vertex Pharmaceuticals: Pioneering New Treatments for Kidney Disorder - TipRanks
Vertex Pharmaceuticals’ VX-880 Study: A Potential Game-Changer for Type 1 Diabetes with Kidney Transplant - TipRanks
Vertex Pharmaceuticals Advances VX-670 Study for Myotonic Dystrophy Type I - TipRanks
Vertex to Participate in the UBS Global Healthcare Conference on November 11 - Business Wire
Vertex Pharmaceuticals’ VX-407 Study: A Potential Game-Changer in Oral Contraceptive Pharmacokinetics - TipRanks
Vertex Pharmaceuticals’ Promising Cystic Fibrosis Study: A Potential Game-Changer - TipRanks
Vertex’s VX-880 Study: A Potential Game-Changer for Type 1 Diabetes - TipRanks
Vertex Pharmaceuticals Advances Cystic Fibrosis Treatment with New Pediatric Study - TipRanks
Vertex Pharmaceuticals Advances Sickle Cell Disease Treatment with Exa-cel Study - TipRanks
Vertex Pharmaceuticals Advances VX-670 Study for Myotonic Dystrophy Type 1 - TipRanks
Vertex Pharmaceuticals Advances with Promising CRISPR Gene-Editing Study - TipRanks
0.90%
7.78%
大文字化:
|
ボリューム (24 時間):